SOX2 and melanoma: We found that pharmacological inhibition of the drug efflux transporter BCRP/ABCG2 with either 1 μM GF-120918 (elacridar) or 5 μM KO-143 led to increased melanoma cell sensitivity to PLX4032 in SOX2-expressing A375 and A2058 cells (Figs. 7, G and H and S12), without impacting on that of SOX2-depleted cells.